{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T00:32:54Z","timestamp":1794875574122,"version":"4.9.1"},"reference-count":27,"publisher":"American Society of Hematology","issue":"3","license":[{"start":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T00:00:00Z","timestamp":1698019200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,2,13]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Outcomes in patients with relapsed diffuse large B-cell lymphoma (DLBCL) who undergo autologous stem cell transplant (auto-SCT) are poor. Blinatumomab is a CD3\/CD19 bispecific T-cell engager that directs cytotoxic T cells to CD19+ cells. Here, we performed a pilot study of blinatumomab consolidation after auto-SCT for 14 patients with DLBCL or transformed follicular lymphoma. All patients underwent standard-of-care auto-SCT with carmustine, etoposide, cytarabine, and melphalan (BEAM) conditioning followed by 1 cycle (4\u00a0weeks continuous infusion) of blinatumomab consolidation starting at day 42 after auto-SCT. All 14 patients treated on study completed BEAM auto-SCT and 1 cycle of posttransplant blinatumomab. Five patients developed grade 1 cytokine release syndrome (CRS), with no grade 2 or higher CRS. Immune effector cell\u2013associated neurotoxicity syndrome was not observed. Patients were followed up for 3 years after auto-SCT, with median follow-up of 37 (range, 12-65) months. One-hundred days after auto-SCT (1\u00a0month after blinatumomab consolidation), 12 patients (86%) had achieved complete remission. At 1 year after auto-SCT, 7 patients (50%) remained in CR, and 1 patient had died of progressive disease. Patients who relapsed had a lower CD8:CD4 T-cell ratio before starting blinatumomab than patients who remained in remission. This pilot study demonstrates blinatumomab consolidation after auto-SCT is safe and well tolerated. Strategies to increase the CD8:CD4 ratio and use additional cycles of consolidation in a larger randomized trial are needed to confirm the efficacy of consolidation with blinatumomab after auto-SCT. This trial was registered at www.clinicaltrials.gov as #NCT03072771.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011130","type":"journal-article","created":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T20:51:52Z","timestamp":1698094312000},"page":"513-522","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Blinatumomab consolidation post\u2013autologous stem cell transplantation in patients with diffuse large B-cell lymphoma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8848-8474","authenticated-orcid":false,"given":"Armin","family":"Ghobadi","sequence":"first","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3862-0232","authenticated-orcid":false,"given":"Nicole C.","family":"Foley","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jared","family":"Cohen","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Rettig","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda F.","family":"Cashen","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5944-7868","authenticated-orcid":false,"given":"Leah","family":"Gehrs","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Christ","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Street","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Wallace","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Ritchey","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5744-0670","authenticated-orcid":false,"given":"Neha","family":"Mehta-Shah","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Westervelt","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8705-2887","authenticated-orcid":false,"given":"Todd A.","family":"Fehniger","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Kahl","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8470-394X","authenticated-orcid":false,"given":"Nancy L.","family":"Bartlett","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"DiPersio","sequence":"additional","affiliation":[{"name":"Washington University School of Medicine, Department of Medicine, Division of Medical Oncology, St. Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,1,24]]},"reference":[{"key":"2024021216544098000_bib1","unstructured":"Howlader\n              N\n            , KrapchoM, GarshellJ, . SEER Cancer Statistics Review 1975-2012. National Cancer Institute. Accessed 7 January 2024. http:\/\/seer.cancer.gov\/csr\/1975_2012."},{"issue":"6","key":"2024021216544098000_bib2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"123","author":"Zhou","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2024021216544098000_bib3","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin\u2019s lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"2024021216544098000_bib4","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024021216544098000_bib5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.bbmt.2009.08.011","article-title":"A\u00a0comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR","volume":"16","author":"Lazarus","year":"2010","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024021216544098000_bib6","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ijc.20908","article-title":"Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-\/CD3-bispecific single-chain antibody construct","volume":"115","author":"Hoffmann","year":"2005","journal-title":"Int J Cancer"},{"issue":"36","key":"2024021216544098000_bib7","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"2024021216544098000_bib8","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"14","key":"2024021216544098000_bib9","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","article-title":"Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia","volume":"131","author":"G\u00f6kbuget","year":"2018","journal-title":"Blood"},{"issue":"11","key":"2024021216544098000_bib10","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B-cell lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"issue":"6","key":"2024021216544098000_bib11","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood.V95.6.2098","article-title":"A\u00a0recombinant bispecific single-chain antibody, CD19 x CD3, induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes","volume":"95","author":"L\u00f6ffler","year":"2000","journal-title":"Blood"},{"issue":"1","key":"2024021216544098000_bib12","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"issue":"8","key":"2024021216544098000_bib13","first-page":"832","article-title":"Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications","volume":"85","author":"Steingrimsdottir","year":"2000","journal-title":"Haematologica"},{"issue":"6","key":"2024021216544098000_bib14","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.bbmt.2014.03.007","article-title":"Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma","volume":"20","author":"Rueff","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"24","key":"2024021216544098000_bib15","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/blood-2015-06-649111","article-title":"Long-term survival and T-cell kinetics in relapsed\/refractory ALL patients who achieved MRD response after blinatumomab treatment","volume":"126","author":"Zugmaier","year":"2015","journal-title":"Blood"},{"issue":"24","key":"2024021216544098000_bib16","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"issue":"3","key":"2024021216544098000_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nri3158","article-title":"Standardizing immunophenotyping for the Human Immunology Project","volume":"12","author":"Maecker","year":"2012","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"2024021216544098000_bib18","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"16","key":"2024021216544098000_bib19","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1182\/bloodadvances.2019000025","article-title":"Long-term outcome of patients with relapsed\/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab","volume":"3","author":"Dufner","year":"2019","journal-title":"Blood Adv"},{"issue":"5891","key":"2024021216544098000_bib20","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"issue":"9","key":"2024021216544098000_bib21","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1080\/10428194.2022.2064981","article-title":"Open-label, phase 2 study of blinatumomab after frontline R-chemotherapy in adults with newly diagnosed, high-risk DLBCL","volume":"63","author":"Katz","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2024021216544098000_bib22","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1038\/s41375-020-01089-x","article-title":"Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia","volume":"35","author":"Wei","year":"2021","journal-title":"Leukemia"},{"issue":"12","key":"2024021216544098000_bib23","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"issue":"13","key":"2024021216544098000_bib24","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","article-title":"Phase III randomized study of rituximab\/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 Trial","volume":"31","author":"Vose","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"2024021216544098000_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clml.2021.09.011","article-title":"Refractory DLBCL: challenges and treatment","volume":"22","author":"Goldfinger","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2024021216544098000_bib26","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1182\/blood-2021-152822","article-title":"A Phase 1b study of blinatumomab including subcutaneous administration in relapsed\/refractory (R\/R) indolent non Hodgkin\u2019s lymphoma (NHL)","volume":"138","author":"Rossi","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024021216544098000_bib27","doi-asserted-by":"crossref","first-page":"6122","DOI":"10.1182\/blood-2022-157117","article-title":"Safety and pharmacokinetics of subcutaneous blinatumomab (SC blinatumomab) for the treatment of adults with relapsed or refractory B cell precursor acute lymphoblastic leukemia (R\/R B-ALL); results from a phase 1b study","volume":"140","author":"Mart\u00ednez S\u00e1nchez","year":"2022","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/3\/513\/2212806\/blooda_adv-2023-011130-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/3\/513\/2212806\/blooda_adv-2023-011130-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T16:54:58Z","timestamp":1707756898000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/3\/513\/498395\/Blinatumomab-consolidation-post-autologous-stem"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,24]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,2,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011130","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,24]]}}}